McKnight Clinical Translational Research Scholarship in Cognitive Aging and Age-Related Memory Loss

2 years

Each award will consist of a commitment of $65,000 per year for two years, plus a $10,000 per year stipend to support education and research-related costs for a total of $150,000.

1. For the purpose of this scholarship, research is defined as “patient-oriented research conducted with human participants, or translational research specifically designed to develop treatments or enhance diagnosis of neurologic disease. These may include epidemiologic or behavioral studies, clinical trials, studies of disease mechanisms, the development of new technologies, and health services and outcomes research.” Disease-related studies not directly involving humans or human tissue are also encouraged if the primary goal is the development of therapies, diagnostic tests, or other tools to prevent or mitigate neurological diseases. Research studies at the intersection of age-associated cognitive changes and disease-related cognitive impairment may be considered if a strong case can be made for their relevance to cognitive aging and age-related memory loss. However, research that is primarily focused on neurodegenerative diseases (e.g., Alzheimer’s disease) will not be supported.
2. The recipient is interested in an academic career in neurological research and has completed residency or a PhD no more than 5 years prior to the beginning of this award (July 1, 2024). If you have completed both residency and a PhD, your eligibility is based on when you completed residency. If you completed a fellowship of any kind after residency, your eligibility is still based on the date you finished residency.
3. The proposed program of training and research must be performed entirely within an institution in the United States accredited by the relevant accrediting authority.
4. Research studies at the intersection of age-associated cognitive changes and disease-related cognitive impairment may be considered if a strong case can be made for their relevance to cognitive aging and age-related memory loss. However, research that is primarily focused on neurodegenerative diseases (e.g., Alzheimer’s disease) will not be supported.
6. The proposed program of training and research must be performed entirely within an institution in the United States accredited by the relevant accrediting authority.